Search for: "TEVA PHARMACEUTICAL INDUSTRIES LTD" Results 161 - 180 of 257
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Feb 2018, 1:31 pm by Gregory Sephton
Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries, Ltd., Case 2016-1284, 2016-1787 (Fed. [read post]
8 Dec 2007, 11:00 am
: (IP Think Tank), WIPO - Idris gets paid out to leave early: (IAM), (Patent Prospector), Deutsche Grammophon ditches DRM: (ArsTechnica)PharmaFDA revisits NCE exclusivity for enantiomers: (Arnall Golden & Gregory), Accupril (Quinapril) - Judge finds against Teva and holds Warner-Lambert patent enabled: (IPLaw360), (OrangeBookBlog), Altace / Tritace / Ramace (Ramipril) - King Pharmaceuticals loses CAFC rehearing bid:… [read post]
17 Nov 2010, 1:48 am by Kelly
(Patently-O) US: Amicus brief filed by Alnylam Pharmaceuticals argues that Funk Bros. is about obviousness, not patent eligibility: AMP v USPTO (Holman’s Biotech IP Blog) US: Amicus briefs in AMP v USPTO: Genetic Alliance (Patent Docs) US: Patent expirations will stabilise the pharmaceutical industry (BiotechBlog) US: Generic industry headed for a ‘180-day exclusivity cliff’ (FDA Law Blog) US: PTO clarifies PTE availability in post-PhotoCure and… [read post]
25 Jan 2017, 11:25 pm
However, claim 27 is to “a pharmaceutical composition comprising a compound according to any one of claims 1-25 together with a pharmaceutically acceptable carrier and optionally other therapeutic ingredients” (emphasis added). [read post]
17 Oct 2008, 1:32 pm
Proposed EU information laws on prescription drugs (IPmed) Iceland: Supplementary Protection Certificates (SPCs) in Iceland (The SPC blog) India: Roche implements 'mass serialisation' anti-counterfeiting technology (Spicy IP) Indonesia: Patent application on oil palm hybrids (navigating the patent maze) United States: New PMCA research: State legislative proposals restricting access to generic medicines would increase cost $29 billion over 10 years (GenericsWeb) US:… [read post]
3 Aug 2020, 7:02 am by Elizabeth McAuliffe (Bristows)
Where there are specialists with a focus on the kind of work with which a patent is concerned, they are the relevant addressees of the patent and their specialist skills are attributed to the notional skilled person, even if the patent might also be of a broader application and of interest to non-specialists (Medimmune Ltd v Novartis Pharmaceuticals UK Ltd [2013] RPC 27). [read post]
16 May 2019, 9:30 am by Silver Law Group
Frost is a biotech billionaire who is CEO and chairman of Opko Health and former chairman of Teva Pharmaceutical Industries Ltd. [read post]
10 Aug 2010, 8:44 pm by Marie Louise
  General Coverage of anti-counterfeit policy debate varies widely across global media (IP Watch) WHO declares flu pandemic over; experts behind response to be revealed (IP Watch) Australia: TGA to implement alert system for new ARTG registrations (IP Whiteboard) EU: Final petition of the Advocate-General / Jodosulfuron- SPC for plant protection products (EPLAW) India: Parliamentary Committee on Health tables report on issues relating to availability of generic medicines (Spicy IP) Peru:… [read post]
23 Nov 2007, 9:00 am
You can separately subscribe to the IP Thinktank Global week in Review at []GlobalReputation and privacy in the online social media world: (IPWar's), McAfee typosquatting study results and implications: (IPWar's),Larry Lessig's comments on how creativity is being strangled by the law: (BLOG@IP::JUR)Two interesting papers on Creative Commons: (CreativeCommons)Friction and 'Warfighting': (IP Think Tank),More on the controversy at WIPO over Kamil Idris'… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
1 Jul 2009, 7:14 am
(Patent Docs) Products Avapro (Irbesartan) – Spain: Fourth Commercial Court of Barcelona rejects preliminary injunction petition by Sanofi-Aventis and Bristol-Myers Squibb for alleged patent infringement (International Law Office) Cozaar/Hyzaar (Losartan/Hydrochlorothiazide and Losartan) –US: Teva sues FDA over generic Cozaar and Hyzaar 180-day exclusivity forfeiture and patent delisting rule (The FDA Law Blog) Eloxatin (Oxaliplatin) – US: District Court of… [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
9 Sep 2009, 7:14 am
(America-Israel Patent Law) USPTO says some requests for patent term adjustment reconsideration are premature (Patent Docs) US: New York Times article ‘For Profit, Industry Seeks Cancer Drugs’ reports on cancer drug development (Patent Docs)   Products Angiomax (Bivalirudin) – US: Last-minute extension of pharmaceutical product life, or just throwing up a smokescreen? [read post]
23 Jan 2009, 12:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: []   Highlights this week included: India: Discussion of Delhi High Court Dasatinib order – patent linkage between Indian Patent Office and Office of the Drug Controller General of India (Patent Circle) (Spicy IP) (Patent Circle) (Managing Intellectual Property) Lescol (Fluvastatin) – US: EWHC finds sustained release Fluvastatin patent invalid on ground of… [read post]